Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) FCF Margin (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed FCF Margin for 6 consecutive years, with 542583.33% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 10910152.0% to 542583.33% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 418900.0% through Dec 2025, down 15191967.0% year-over-year, with the annual reading at 418900.0% for FY2025, 15191967.0% down from the prior year.
  • FCF Margin hit 542583.33% in Q4 2025 for Lyell Immunopharma, down from 193626.67% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 461.45% in Q3 2021 to a low of 1774800.0% in Q3 2022.
  • Historically, FCF Margin has averaged 333086.15% across 5 years, with a median of 150370.59% in 2023.
  • Biggest five-year swings in FCF Margin: plummeted -177526145bps in 2022 and later soared 161354400bps in 2023.
  • Year by year, FCF Margin stood at 3305.63% in 2021, then surged by 97bps to 92.69% in 2022, then tumbled by -337336bps to 312769.23% in 2023, then plummeted by -39bps to 433481.82% in 2024, then fell by -25bps to 542583.33% in 2025.
  • Business Quant data shows FCF Margin for LYEL at 542583.33% in Q4 2025, 193626.67% in Q3 2025, and 427762.5% in Q2 2025.